Patents Examined by Brian Gangle
  • Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
    Patent number: 11690899
    Abstract: The present invention relates to the field of medicine, specifically the field of bacterial infection and treatment thereof.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: July 4, 2023
    Assignee: Micreos Human Health B.V.
    Inventor: Fritz Eichenseher
  • Tetanus toxoid and CCL3 improve DC vaccines
    Patent number: 11684662
    Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
    Type: Grant
    Filed: July 11, 2021
    Date of Patent: June 27, 2023
    Assignee: Duke University
    Inventors: John H Sampson, Duane A Mitchell, Kristen A Batich, Michael D Gunn
  • Peptides and antibodies for the removal of biofilms
    Patent number: 11684673
    Abstract: This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that are released from the biofilm by our technology are more readily cleared by the remainder of the host's immune system.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: June 27, 2023
    Assignee: Research Institute at Nationwide Children's Hospital
    Inventors: Lauren O. Bakaletz, Steven D. Goodman
  • host-pathogen interaction
    Patent number: 11680296
    Abstract: Gene expression signatures and pathways associated with tuberculosis are identified. The invention provides for diagnostic assays based on gene markers and cell composition, as well as therapeutic targets for modulating tuberculosis infection. In addition, tuberculosis copy number contained in cells and methods of detecting high and low copy number are disclosed.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: June 20, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Alexander K. Shalek, Carly Ziegler
  • Composition for use in the treatment and/or improvement of sleep and mood disorders
    Patent number: 11679135
    Abstract: The present invention refers to a composition for use in the treatment of sleep disorder, in particular, in the improvement of sleep quality. Furthermore, the present invention refers to a composition for use in the treatment of mood modulation.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: June 20, 2023
    Assignee: PROBIOTICAL S.P.A.
    Inventors: Marco Pane, Angela Amoruso, Mirta Fiorio, Angela Marotta, Giovanna Felis, Antonio Del Casale
  • Composition and methods for microbiota therapy
    Patent number: 11679136
    Abstract: The present invention provides a composition comprising a co-culture of at least two distinct bacterial families, having differing growth and/or proliferative conditions. In some embodiments, the composition comprises a plurality of bacterial genera with high similarity to microbial flora.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: June 20, 2023
    Assignee: MYBIOTICS PHARMA LTD.
    Inventors: David Baram, David Daboush, Rachel Diamant
  • Composition for promoting local muscle growth or slowing down or preventing local muscle atrophy and use thereof
    Patent number: 11672845
    Abstract: Disclosed is a composition for promoting local muscle growth or slowing down or preventing local muscle atrophy, which composition contains a polypeptide in the C2 region of the enterotoxin Staphylococcus aureus and a myostatin polypeptide. By means of the composition, the defect in the prior art of only systemic muscle growth being possible has been overcome so as to achieve effects of promoting local muscle growth, or slowing down or preventing local muscle atrophy.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: June 13, 2023
    Assignee: SOULYOUNG BIOTECH CO., LTD.
    Inventor: Hsun-Jin Jan
  • Composition for prevention or treatment of neurological or mental disorders comprising extracellular vesicles derived from
    Patent number: 11672838
    Abstract: Provided are a method for preventing, improving, or treating a neurological disorder, mental disorder, senescence, or symptoms thereof, comprising administering to a subject in need thereof vesicles derived from Lactobacillus paracasei as an active ingredient, and a pharmaceutical or functional food composition comprising the vesicles.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: June 13, 2023
    Assignee: MD HEALTHCARE INC.
    Inventor: Yoon-Keun Kim
  • Method for treating individuals having cancer and who are receiving cancer immunotherapy
    Patent number: 11672835
    Abstract: The methods described herein are for treating infections in individuals having cancer and who are receiving cancer immunotherapy, preferably employing a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and thereafter, administering an immune checkpoint inhibitor thereto. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa, Klebsiella bacteria, Staphylococcus aureus; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; Clostridium; Neisseria gonnorrhoea; Acinetobacter baumannii; and Campylobacter bacteria and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: June 13, 2023
    Assignee: Seed Health, Inc.
    Inventor: Joseph E. Kovarik
  • Platform for generating safe cell therapeutics
    Patent number: 11674121
    Abstract: Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.
    Type: Grant
    Filed: February 4, 2022
    Date of Patent: June 13, 2023
    Assignee: The Regents of the University of California
    Inventors: Richard Klemke, Huawei Wang
  • Proteins for the treatment of epithelial barrier function disorders
    Patent number: 11666627
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: June 6, 2023
    Assignee: Second Genome, Inc.
    Inventors: Andrew Wonhee Han, Andrew Whitman Goodyear, Tarunmeet Gujral, Todd Zachary Desantis, Karim Dabbagh, Toshihiko Takeuchi, Ye Jin, Michi Izumi Willcoxon, Stefanie Banas
  • Methods of treating dog urinary tract infections
    Patent number: 11666609
    Abstract: Provided are methods for treating acute and recurring urinary tract infections in dogs.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: June 6, 2023
    Assignees: The Regents of the University of California, Northwestern University
    Inventors: JoEllen L. Westropp, Anthony J. Schaeffer, David J. Klumpp
  • Global gene regulators (GGR) as vaccine candidates against
    Patent number: 11655447
    Abstract: Described herein is a Mycobacterium mutant, comprising at least one mutation in at least one gene sequence encoding global gene regulators (GGRs) selected from the group consisting of sigH, sigL, sigE, ECF-1, and mixtures thereof, wherein the GGR gene is at least partially inactivated. Described herein also is a vaccine based on the mutant and a method of differentiating between subjects that have been infected with Mycobacterium and subjects that have not been infected with Mycobacterium or have been vaccinated with a Mycobacterium vaccine.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: May 23, 2023
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventor: Adel M. Talaat
  • Horn fly protein as active antigen in anti-horn fly vaccine for protection of bovines against horn fly infestations
    Patent number: 11654187
    Abstract: Antigenic polypeptides derived from a naturally occurring horn fly protein, and nucleic acid molecules encoding the polypeptides, are described. The polypeptides elicit an immune response which, in turn, produces detrimental effects in horn flies feeding on vaccinated cattle. Thus, the present disclosure provides a novel horn fly vaccine.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: May 23, 2023
    Assignee: The United States of America, as represented by The Secretary of Agriculture
    Inventors: Felicito Guerrero, Luisa N. Domingues
  • combination for administration to animals
    Patent number: 11653674
    Abstract: Embodiments of a composition comprising three or four Bacillus species selected from Bacillus amyloliquefaciens, Bacillus subtilis, Bacillus licheniformis and Bacillus coagulans are disclosed. The composition may further comprise, or be used in combination with, feed and/or feed supplements, including feed supplements comprising Yucca, Quillaja, silica, mineral clay, glucan, mannans, or combinations thereof. Also disclosed is a method of administering the composition and/or combination to animals, such as poultry.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: May 23, 2023
    Assignee: OmniGen Research, LLC
    Inventors: A. Bruce Johnson, Kenneth W. Bafundo
  • Glycosylated YghJ polypeptides from enterotoxigenic (ETEC)
    Patent number: 11655274
    Abstract: The present invention relates to glycosylated YghJ polypeptides from or derived from enterotoxigenic Escherichia coli (ETEC) that are immunogenic. In particular, the present invention relates to compositions or vaccines comprising the polypeptides and their application in immunization, vaccination, treatment and diagnosis of ETEC.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: May 23, 2023
    Assignees: Aarhus Universitet, Syddansk Universitet
    Inventors: Anders Boysen, Jakob Møller-Jensen, Giuseppe Palmisano, Martin Røssel Larsen
  • Nanoemulsion and methods of use thereof
    Patent number: 11642405
    Abstract: The present disclosure relates to compositions and methods for inducing an immune response to a composition of the invention in a subject. Additionally, the present disclosure generally relates to methods for screening for immune response to a composition of the invention.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: May 9, 2023
    Assignees: Washington University, BLUEWILLOW BIOLOGICS
    Inventors: Shabaana Abdul Khader, Mushtaq Ahmed, Ali Fattom, Douglas Smith, Tarek Hamouda
  • Treating and preventing microbial infections
    Patent number: 11643653
    Abstract: The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: May 9, 2023
    Assignee: SNIPR Biome ApS
    Inventors: Morten Sommer, Virginia Martinez, Eric Van Der Helm, Jakob Krause Haaber, Ana De Santiago Torio, Christian Grøndahl, Jasper Clube
  • Administration of an anti-interleukin 12/23 antibody for treatment of autoimmune disease
    Patent number: 11643460
    Abstract: The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of ustekinumab is administered to the subject. Oral administration of ustekinumab also is useful in a method of decreasing innate inflammatory cytokines, such as Interleukin-1? and Tumor Necrosis Factor-?, Th1-like cytokines Interleukin-2 and Interferon-?, Interleukin-17 (Teff), Interleukin-12p70, and increasing Th2-like counter-regulatory cytokine Interleukin-13 in a subject.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: May 9, 2023
    Inventor: Staley Brod
  • Serum biomarkers for predicting and evaluating response to TNF inhibitor therapy in rheumatoid arthritis patients
    Patent number: 11644473
    Abstract: The present disclosure is directed to methods and kits for using serum biomarkers, including C-X-C Motif Chemokine Ligand 10 (CXCL10), C-X-C Motif Chemokine Ligand 13 (CXCL13), and/or soluble CD27 (sCD27), in predicting and evaluating therapeutic response to Tumor Necrosis Factor (TNF) inhibitor therapy in a patient in need thereof.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: May 9, 2023
    Assignee: Rowan University
    Inventors: Kwanghoon Han, Andrea Bottaro, Nancy J. Olsen